ImmunityBio's ANKTIVA achieves record revenue and global cancer treatment approvals
ImmunityBio has made major strides in natural killer (NK) cell therapy, with its lead product ANKTIVA achieving record revenue and expanded approvals. The treatment generated $113 million in 2025, marking a sevenfold increase from the previous year. Regulators in 33 countries, including China, have now greenlit its use for certain cancers, broadening access for patients worldwide.
The company's progress includes a recent submission to the US Food and Drug Administration (FDA). ImmunityBio filed a supplemental Biologics License Application (BLA) for ANKTIVA combined with BCG in patients with BCG-unresponsive non-muscle-invasive bladder cancer. This follows the completion of a Phase I trial, QUILT-3.076, which confirmed the safety of M-ceNK cells alongside ANKTIVA in patients with recurrent or refractory tumours. No serious side effects were observed in the 23 doses given to ten participants.
Preclinical research has also shown promise. In two xenograft models of small-cell lung cancer, the combination of M-ceNK cells and ANKTIVA significantly reduced tumour volume. The therapy's potential extends to tumours resistant to traditional T cell-based treatments, such as neuroendocrine cancers, which often lack MHC class I expression. These findings align with broader studies demonstrating that NK cells from cancer patients can match the tumour-killing ability of those from healthy donors, even against resistant cell lines. Behind these advances lies a scalable production platform. ImmunityBio's system can generate up to five billion NK cells from a single leukapheresis procedure—enough for eight to ten treatment doses in just 12 days. This efficiency supports wider clinical and commercial use of their therapies.
ANKTIVA's rapid revenue growth and expanding approvals reflect its growing role in cancer treatment. With ongoing trials, a validated production process, and encouraging preclinical results, ImmunityBio continues to push forward in NK cell-based immunotherapy. The company's focus remains on addressing unmet needs in bladder, lung, and other solid tumours.
Read also:
- India's Agriculture Minister Reviews Sector Progress Amid Heavy Rains, Crop Areas Up
- Cyprus, Kuwait Strengthen Strategic Partnership with Upcoming Ministerial Meeting
- Inspired & Paddy Power Extend Virtual Sports Partnership for UK & Ireland Retail
- South West & South East England: Check & Object to Lorry Operator Licensing Now
